Supplementary Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)
Publication
, Other
Nixon, AB; Halabi, S; Liu, Y; Starr, MD; Brady, JC; Shterev, I; Luo, B; Hurwitz, HI; Febbo, PG; Rini, BI; Beltran, H; Small, EJ; Morris, MJ ...
March 31, 2023
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Nixon, A. B., Halabi, S., Liu, Y., Starr, M. D., Brady, J. C., Shterev, I., … George, D. J. (2023). Supplementary Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance). https://doi.org/10.1158/1078-0432.22484208.v1
Nixon, Andrew B., Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev, Bin Luo, et al. “Supplementary Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance),” March 31, 2023. https://doi.org/10.1158/1078-0432.22484208.v1.
Nixon AB, Halabi S, Liu Y, Starr MD, Brady JC, Shterev I, et al. Supplementary Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance). 2023.
Nixon, Andrew B., et al. Supplementary Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance). 31 Mar. 2023. Crossref, doi:10.1158/1078-0432.22484208.v1.
Nixon AB, Halabi S, Liu Y, Starr MD, Brady JC, Shterev I, Luo B, Hurwitz HI, Febbo PG, Rini BI, Beltran H, Small EJ, Morris MJ, George DJ. Supplementary Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance). 2023.